IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics
GET POWR RATINGS... FREE!
IGMS Stock Price Chart Interactive Chart >
IGMS Price/Volume Stats
| Current price | $22.45 | 52-week high | $65.08 |
| Prev. close | $22.07 | 52-week low | $12.67 |
| Day low | $21.87 | Volume | 101,381 |
| Day high | $23.19 | Avg. volume | 568,146 |
| 50-day MA | $20.75 | Dividend yield | N/A |
| 200-day MA | $19.37 | Market Cap | 954.73M |
IGM BIOSCIENCES, INC. (IGMS) Company Bio
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
Latest IGMS News From Around the Web
Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.
IGM Biosciences to Present at Three Upcoming Investor ConferencesMOUNTAIN VIEW, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in three upcoming investor conferences in New York: Fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12 at 1:40 p.m. ESTFireside chat at the Baird 2022 Global Healthcare Conference on Tu |
IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
|
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue EstimatesIGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? |
IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing of Collaboration Agreement with Sanofi – MOUNTAIN VIEW, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent develo |
IGM Biosciences, Inc. (NASDAQ:IGMS) insiders placed bullish bets worth US$2.3m in the last 12 monthsIn the last year, multiple insiders have substantially increased their holdings of IGM Biosciences, Inc. ( NASDAQ:IGMS... |
IGMS Price Returns
| 1-mo | 20.57% |
| 3-mo | 8.19% |
| 6-mo | 3.89% |
| 1-year | -62.72% |
| 3-year | 23.49% |
| 5-year | N/A |
| YTD | -23.46% |
| 2021 | -66.78% |
| 2020 | 131.37% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...